Respuesta :
Gemcitabine has been demonstrated to enhance outcomes in patients with locally advanced metastatic pancreatic cancer when compared to fluorouracil.
The goal of this study is to see if adding gemcitabine to adjuvant fluorouracil chemoradiation (chemotherapy with radiation) improves survival in patients with resected pancreatic adenocarcinoma. Patients with full gross total resection of pancreatic adenocarcinoma with no previous radiation or chemotherapy were included in a randomized controlled phase 3 study at 164 US and Canadian institutions between July 1998 and July 2002, with follow-up until August 18, 2006. Fluorouracil (continuous infusion of 250 mg/m2 per day; n = 230) or gemcitabine (30-minute infusion of 1000 mg/m2 once per week; n = 221) chemotherapy for 3 weeks before to and 12 weeks following chemoradiation treatment.
The addition of gemcitabine to adjuvant fluorouracil-based chemoradiation was related with improved survival in patients with resected pancreatic cancer, albeit this advantage was not statistically significant.
To learn more about Chemotherapy from the given link
https://brainly.com/question/19210844
#SPJ4
